Multiple Myeloma:@0.747978:0.035749:0.914540:0.035749:0.914540:0.019993:0.747978:0.019993:0.017684:0.011699:0.003848:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.017684:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143
TREATMENT APPROACHES:@0.983689:0.278245:0.983689:0.065272:0.955679:0.065272:0.955679:0.278245:0.000000:0.000000:0.000000:0.057096:-0.123230:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.000000:0.375913
87:@0.955522:0.038184:0.976595:0.038184:0.976595:0.018587:0.955522:0.018587:0.010536:0.010536
HANDBOOK OF ONCOLOGY:@0.679047:0.970015:0.915156:0.970015:0.915156:0.956010:0.679047:0.956010:0.011682:0.012657:0.012657:0.012726:0.009818:0.014864:0.014864:0.010109:0.004738:0.014864:0.008296:0.004738:0.014864:0.012657:0.013906:0.014864:0.007902:0.014864:0.014915:0.010126
neuropathy rarely occurs; if it does, it is :@0.084242:0.862832:0.480449:0.862832:0.480449:0.847076:0.084242:0.847076:0.011738:0.012508:0.011699:0.005707:0.012604:0.013123:0.013143:0.006523:0.011738:0.010314:0.009948:0.005792:0.013143:0.005709:0.012508:0.003848:0.010314:0.009948:0.012604:0.012450:0.012450:0.011699:0.005792:0.007466:0.005330:0.009948:0.003848:0.006042:0.009948:0.003848:0.006523:0.009948:0.013181:0.012604:0.012508:0.007466:0.005330:0.009948:0.003848:0.006523:0.009948:0.003848:0.007466:0.005330
usually in the  setting  of amyloidosis or :@0.084242:0.881181:0.480480:0.881181:0.480480:0.865425:0.084242:0.865425:0.011699:0.007466:0.011699:0.013143:0.003848:0.003848:0.010314:0.012931:0.003848:0.011738:0.012931:0.006523:0.011738:0.012508:0.005330:0.007589:0.007466:0.012508:0.006523:0.006523:0.003848:0.011738:0.012950:0.005330:0.007591:0.012604:0.006042:0.012931:0.013143:0.018049:0.010314:0.003848:0.012604:0.003848:0.013181:0.012604:0.007466:0.003848:0.007466:0.012931:0.012604:0.005792:0.005330
POEMS  syndrome.  Occasionally, patients :@0.084242:0.899530:0.480482:0.899530:0.480482:0.883774:0.084242:0.883774:0.011392:0.016722:0.010314:0.017684:0.009583:0.005330:0.003512:0.007466:0.010314:0.011738:0.013181:0.005719:0.012604:0.018049:0.012508:0.005330:0.005330:0.003508:0.016722:0.012450:0.012450:0.013143:0.007466:0.003848:0.012604:0.011738:0.013143:0.003848:0.003848:0.010314:0.005330:0.008852:0.013123:0.013143:0.006523:0.003848:0.012508:0.011738:0.006523:0.007466:0.005330
may present with headaches or blurred vi-:@0.084242:0.917879:0.475142:0.917879:0.475142:0.902123:0.084242:0.902123:0.018049:0.013143:0.010314:0.004791:0.013123:0.005715:0.012508:0.007466:0.012508:0.011738:0.006523:0.004778:0.015990:0.003848:0.006523:0.011738:0.004776:0.011738:0.012508:0.013143:0.013181:0.013143:0.012450:0.011738:0.012508:0.007466:0.004782:0.012604:0.005792:0.004774:0.013123:0.003848:0.011699:0.005792:0.005713:0.012508:0.013181:0.004782:0.010660:0.003848:0.006388
sion due to hyperviscosity.:@0.084242:0.936228:0.326389:0.936228:0.326389:0.920472:0.084242:0.920472:0.007466:0.003848:0.012604:0.011738:0.005330:0.013181:0.011699:0.012508:0.005330:0.006523:0.012604:0.005330:0.011738:0.010314:0.013123:0.012508:0.005792:0.010660:0.003848:0.007466:0.012450:0.012604:0.007466:0.003848:0.006523:0.010314:0.005330
USEFUL LABORATORY TESTS:@0.523636:0.862744:0.819499:0.862744:0.819499:0.843147:0.523636:0.843147:0.015052:0.012230:0.012230:0.011289:0.015052:0.010348:0.006585:0.010348:0.017404:0.013641:0.019756:0.013641:0.017404:0.009878:0.019756:0.013641:0.014581:0.006585:0.009878:0.012230:0.012230:0.009878:0.012230
n   :@0.523636:0.879720:0.546445:0.879720:0.546445:0.871279:0.523636:0.871279:0.009762:0.003566:0.005914:0.003566
Full blood count (FBC) and peripheral :@0.542878:0.882839:0.904601:0.882839:0.904601:0.867083:0.542878:0.867083:0.009525:0.011892:0.004041:0.004041:0.005523:0.013316:0.004041:0.012796:0.012796:0.013373:0.005523:0.012642:0.012796:0.011892:0.011930:0.006716:0.005523:0.007293:0.009525:0.011238:0.015836:0.007293:0.005523:0.013335:0.011930:0.013373:0.005523:0.013316:0.012700:0.005984:0.004041:0.013316:0.011930:0.012700:0.005984:0.013335:0.003852:0.005330
smear:@0.542878:0.900645:0.600605:0.900645:0.600605:0.884889:0.542878:0.884889:0.007658:0.018242:0.012700:0.013335:0.005792
Apart  from the anaemia as described, :@0.523636:0.918452:0.919883:0.918452:0.919883:0.902696:0.523636:0.902696:0.014239:0.013123:0.013143:0.005792:0.006523:0.005330:0.006533:0.006042:0.005713:0.012604:0.018049:0.011873:0.006523:0.011738:0.012508:0.011873:0.013143:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.011873:0.013143:0.007466:0.011873:0.013181:0.012508:0.007466:0.012450:0.005792:0.003848:0.013123:0.012508:0.013181:0.005330:0.005330
other  compatible  and  useful  findings  on :@0.523636:0.936258:0.919881:0.936258:0.919881:0.920502:0.523636:0.920502:0.012604:0.006523:0.011738:0.012508:0.005792:0.005330:0.003972:0.012450:0.012604:0.018049:0.013123:0.013143:0.006523:0.003848:0.013123:0.003848:0.012508:0.005330:0.003991:0.013143:0.011738:0.013181:0.005330:0.003989:0.011699:0.007466:0.012508:0.006042:0.011699:0.003848:0.005330:0.003987:0.004686:0.004686:0.011738:0.013181:0.003848:0.011738:0.012950:0.007466:0.005330:0.003983:0.012604:0.011738:0.005330
Table 1. Revised International Myeloma Working Group diagnostic criteria for multiple :@0.084236:0.096180:0.867020:0.096180:0.867020:0.080146:0.084236:0.080146:0.007889:0.012508:0.012508:0.004426:0.012123:0.005195:0.010583:0.005195:0.005195:0.010968:0.012123:0.010583:0.004426:0.008274:0.012123:0.012508:0.005195:0.005195:0.011353:0.005580:0.012123:0.005965:0.011353:0.012508:0.005580:0.004426:0.012123:0.011353:0.012508:0.004426:0.005195:0.017126:0.010968:0.012123:0.004426:0.012123:0.017895:0.012508:0.005195:0.017126:0.012123:0.005965:0.010968:0.004426:0.011353:0.012508:0.005195:0.015971:0.005965:0.012123:0.011353:0.012508:0.005195:0.012508:0.004426:0.012508:0.012508:0.011353:0.012123:0.008274:0.005580:0.004426:0.012123:0.005195:0.012123:0.005965:0.004426:0.005580:0.012123:0.005965:0.004426:0.012508:0.005195:0.005195:0.012123:0.005965:0.005195:0.017895:0.011353:0.004426:0.005580:0.004426:0.012508:0.004426:0.012319:0.005388
myeloma and smouldering multiple myeloma:@0.084236:0.112346:0.503143:0.112346:0.503143:0.096312:0.084236:0.096312:0.017895:0.010968:0.012123:0.004426:0.012123:0.017895:0.012508:0.005195:0.012508:0.011353:0.012508:0.005195:0.008274:0.017895:0.012123:0.011353:0.004426:0.012508:0.012123:0.005965:0.004426:0.011353:0.012508:0.005195:0.017895:0.011353:0.004426:0.005580:0.004426:0.012508:0.004426:0.012123:0.005195:0.017895:0.010968:0.012123:0.004426:0.012123:0.017895:0.012700
Definition of multiple myeloma:@0.093868:0.136837:0.372103:0.136837:0.372103:0.120803:0.093868:0.120803:0.013277:0.012123:0.004907:0.004897:0.011353:0.004426:0.005580:0.004426:0.012123:0.011353:0.005195:0.012123:0.005195:0.005195:0.017895:0.011353:0.004426:0.005580:0.004426:0.012508:0.004426:0.012123:0.005195:0.017895:0.010968:0.012123:0.004426:0.012123:0.017895:0.012700
Clonal bone-marrow plasma cells ≥10% of biopsy-proven bony or extramedullary :@0.093868:0.161337:0.857964:0.161337:0.857964:0.145304:0.093868:0.145304:0.015009:0.004618:0.012315:0.011545:0.012700:0.004618:0.005388:0.012700:0.012315:0.011545:0.012315:0.008082:0.018088:0.012700:0.006158:0.006158:0.012315:0.015394:0.005388:0.012700:0.004618:0.012700:0.008467:0.018088:0.012700:0.005388:0.012315:0.012315:0.004618:0.004618:0.008467:0.005388:0.010564:0.010776:0.010776:0.016548:0.005388:0.012315:0.005388:0.005388:0.012700:0.004618:0.012315:0.012700:0.008467:0.011161:0.008082:0.012700:0.006158:0.012315:0.010776:0.012315:0.011545:0.005388:0.012700:0.012315:0.011545:0.011161:0.005388:0.012315:0.006158:0.005388:0.012315:0.010776:0.005773:0.006158:0.012700:0.018088:0.012315:0.012700:0.011545:0.004618:0.004618:0.012700:0.006158:0.011161:0.005388
plasmacytoma* and any one or more of the following myeloma-defining events::@0.093868:0.177503:0.843937:0.177503:0.843937:0.161470:0.093868:0.161470:0.012700:0.004618:0.012700:0.008467:0.018088:0.012700:0.012315:0.011161:0.005773:0.012315:0.018088:0.012700:0.008467:0.005388:0.012700:0.011545:0.012700:0.005388:0.012700:0.011545:0.011161:0.005388:0.012315:0.011545:0.012315:0.005388:0.012315:0.006158:0.005388:0.018088:0.012315:0.006158:0.012315:0.005388:0.012315:0.005388:0.005388:0.005773:0.011545:0.012315:0.005388:0.005388:0.012315:0.004618:0.004618:0.012315:0.015394:0.004618:0.011545:0.012700:0.005388:0.018088:0.011161:0.012315:0.004618:0.012315:0.018088:0.012700:0.008082:0.012700:0.012315:0.005003:0.005003:0.011545:0.004618:0.011545:0.012700:0.005388:0.012315:0.010776:0.012315:0.011545:0.005773:0.008467:0.005388
Evidence of end-organ damage that can be attributed to the underlying plasma-cell :@0.093868:0.202004:0.895776:0.202004:0.895776:0.186248:0.093868:0.186248:0.010314:0.010660:0.003848:0.013181:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.012508:0.011738:0.013181:0.006388:0.012604:0.005792:0.012950:0.013143:0.011738:0.005330:0.013181:0.013143:0.018049:0.013143:0.012950:0.012508:0.005330:0.006523:0.011738:0.013143:0.006523:0.005330:0.012450:0.013143:0.011738:0.005330:0.013123:0.012508:0.005330:0.013143:0.006523:0.006523:0.005792:0.003848:0.013123:0.011699:0.006523:0.012508:0.013181:0.005330:0.006523:0.012604:0.005330:0.006523:0.011738:0.012508:0.005330:0.011699:0.011738:0.013181:0.012508:0.005792:0.003848:0.010314:0.003848:0.011738:0.012950:0.005330:0.013123:0.003848:0.013143:0.007466:0.018049:0.013143:0.006388:0.012450:0.012508:0.003848:0.003848:0.005330
proliferative disorder, specifically::@0.093868:0.218170:0.399955:0.218170:0.399955:0.202414:0.093868:0.202414:0.013123:0.005715:0.012604:0.003848:0.003848:0.006042:0.012508:0.005792:0.013143:0.006523:0.003848:0.010660:0.012508:0.005330:0.013181:0.003848:0.007466:0.012604:0.005678:0.013181:0.012508:0.003768:0.005330:0.005330:0.007466:0.013123:0.012508:0.012450:0.003848:0.004686:0.004686:0.012450:0.013143:0.003848:0.003848:0.010314:0.005330
Hypercalcaemia: serum calcium >0.25 mmol/L (>1 mg/dL) higher than the upper limit :@0.093868:0.234336:0.893163:0.234336:0.893163:0.218580:0.093868:0.218580:0.013143:0.010314:0.013123:0.012508:0.005661:0.012450:0.013143:0.003848:0.012450:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.005330:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330:0.012450:0.013143:0.003848:0.012450:0.003848:0.011699:0.018049:0.005330:0.011661:0.010660:0.005330:0.010660:0.010660:0.005330:0.018049:0.018049:0.012604:0.003848:0.008409:0.008890:0.005330:0.007100:0.011661:0.010660:0.005330:0.018049:0.012950:0.008409:0.013181:0.008890:0.007100:0.005330:0.011738:0.003848:0.012950:0.011738:0.012508:0.005792:0.005330:0.006523:0.011738:0.013143:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.011699:0.013123:0.013123:0.012508:0.005792:0.005330:0.003848:0.003848:0.018049:0.003848:0.006523:0.005330
of normal or >2.75 mmol/L (>11 mg/dL):@0.093868:0.250502:0.456066:0.250502:0.456066:0.234746:0.093868:0.234746:0.012604:0.006042:0.005330:0.011738:0.012604:0.006310:0.018049:0.013143:0.003848:0.005330:0.012604:0.005792:0.005330:0.011661:0.010660:0.005330:0.010660:0.010660:0.005330:0.018049:0.018049:0.012604:0.003848:0.008409:0.008890:0.005330:0.007100:0.011661:0.010660:0.010660:0.005330:0.018049:0.012950:0.008409:0.013181:0.008890:0.007100
Renal insufficiency: creatinine clearance <40 ml per min  or serum creatinine  :@0.093868:0.266668:0.815290:0.266692:0.815290:0.250936:0.093868:0.250912:0.011680:0.012508:0.011738:0.013143:0.003848:0.005330:0.003848:0.011738:0.007466:0.011699:0.006042:0.004686:0.004686:0.012450:0.003848:0.012508:0.011738:0.012450:0.010314:0.005330:0.005330:0.012450:0.005703:0.012508:0.013143:0.006523:0.003848:0.011738:0.003848:0.011738:0.012508:0.005330:0.012450:0.003848:0.012508:0.013143:0.005792:0.013143:0.011738:0.012450:0.012508:0.005330:0.011661:0.010660:0.010660:0.005330:0.018049:0.003848:0.005330:0.013123:0.012508:0.005792:0.005330:0.018049:0.003848:0.011738:0.006315:0.005330:0.012604:0.005792:0.005330:0.007466:0.012508:0.005792:0.011699:0.018049:0.005330:0.012450:0.005690:0.012508:0.013143:0.006523:0.003848:0.011738:0.003848:0.011738:0.012508:0.005330:0.279587
¶:@0.614409:0.261073:0.620736:0.261073:0.620736:0.251888:0.614409:0.251888:0.006327
>177 µmol/L (>2 mg/dL):@0.093859:0.282858:0.314377:0.282858:0.314377:0.267102:0.093859:0.267102:0.011661:0.010660:0.010660:0.010660:0.005330:0.011084:0.018049:0.012604:0.003848:0.008409:0.008890:0.005330:0.007100:0.011661:0.010660:0.005330:0.018049:0.012950:0.008409:0.013181:0.008890:0.007100
Anaemia: haemoglobin value of >2 g/dL below the lower limit of normal, or a :@0.093859:0.299024:0.819756:0.299024:0.819756:0.283268:0.093859:0.283268:0.014239:0.011738:0.013143:0.012508:0.018049:0.003848:0.013143:0.005330:0.005330:0.011738:0.013143:0.012508:0.018049:0.012604:0.012950:0.003848:0.012604:0.013123:0.003848:0.011738:0.005330:0.010660:0.013143:0.003848:0.011699:0.012508:0.005330:0.012604:0.006042:0.005330:0.011661:0.010660:0.005330:0.012950:0.008409:0.013181:0.008890:0.005330:0.013123:0.012508:0.003848:0.012604:0.015990:0.005330:0.006523:0.011738:0.012508:0.005330:0.003848:0.012604:0.015990:0.012508:0.005792:0.005330:0.003848:0.003848:0.018049:0.003848:0.006523:0.005330:0.012604:0.006042:0.005330:0.011738:0.012604:0.006269:0.018049:0.013143:0.003848:0.005330:0.005330:0.012604:0.005792:0.005330:0.013143:0.005330
haemoglobin value <10 g/dL:@0.093859:0.315190:0.364273:0.315190:0.364273:0.299435:0.093859:0.299435:0.011738:0.013143:0.012508:0.018049:0.012604:0.012950:0.003848:0.012604:0.013123:0.003848:0.011738:0.005330:0.010660:0.013143:0.003848:0.011699:0.012508:0.005330:0.011661:0.010660:0.010660:0.005330:0.012950:0.008409:0.013181:0.008890
Bone lesions: one or more osteolytic lesions on skeletal radiography, CT, or PET-CT:@0.093859:0.331357:0.843287:0.331357:0.843287:0.315601:0.093859:0.315601:0.011045:0.012604:0.011738:0.012508:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.005330:0.005330:0.012604:0.011738:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012604:0.005678:0.012508:0.005330:0.012604:0.007466:0.006523:0.012508:0.012604:0.003848:0.010314:0.006523:0.003848:0.012450:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.005330:0.012604:0.011738:0.005330:0.007466:0.009660:0.012508:0.003848:0.012508:0.006523:0.013143:0.003848:0.005330:0.005792:0.013143:0.013181:0.003848:0.012604:0.012950:0.005792:0.013143:0.013123:0.011738:0.010314:0.005330:0.005330:0.015644:0.006208:0.005330:0.005330:0.012604:0.005792:0.005330:0.011392:0.010314:0.008197:0.006388:0.015644:0.008197
Δ:@0.843269:0.325749:0.850135:0.325749:0.850135:0.316564:0.843269:0.316564:0.006866
Any one or more of the following biomarkers of malignancy::@0.093868:0.355873:0.652284:0.355873:0.652284:0.340117:0.093868:0.340117:0.014239:0.011738:0.010314:0.005330:0.012604:0.011738:0.012508:0.005330:0.012604:0.005792:0.005330:0.018049:0.012604:0.005678:0.012508:0.005330:0.012604:0.006042:0.005330:0.006523:0.011738:0.012508:0.005330:0.006042:0.012604:0.003848:0.003848:0.012604:0.015990:0.003848:0.011738:0.012950:0.005330:0.013123:0.003848:0.012604:0.018049:0.013143:0.005792:0.009660:0.012508:0.005792:0.007466:0.005330:0.012604:0.006042:0.005330:0.018049:0.013143:0.003848:0.003848:0.012950:0.011738:0.013143:0.011738:0.012450:0.010314:0.005330
Clonal bone-marrow plasma cell percentage* ≥60%:@0.093868:0.372039:0.578503:0.372039:0.578503:0.356283:0.093868:0.356283:0.015644:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005703:0.012604:0.015990:0.005330:0.013123:0.003848:0.013143:0.007466:0.018049:0.013143:0.005330:0.012450:0.012508:0.003848:0.003848:0.005330:0.013123:0.012508:0.005665:0.012450:0.012508:0.011738:0.006523:0.013143:0.012950:0.012508:0.008178:0.005330:0.010564:0.010660:0.010660:0.014913
Involved: uninvolved serum-free light-chain ratio  ≥100:@0.093868:0.388205:0.594747:0.388211:0.594747:0.372455:0.093868:0.372450:0.004349:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.005330:0.005330:0.011699:0.011738:0.003848:0.011738:0.010660:0.012604:0.003848:0.010660:0.012508:0.013181:0.005330:0.007466:0.012508:0.005792:0.011699:0.018049:0.006388:0.006042:0.005709:0.012508:0.012508:0.005330:0.003848:0.003848:0.012950:0.011738:0.006523:0.006388:0.012450:0.011738:0.013143:0.003848:0.011738:0.005330:0.005792:0.013143:0.006523:0.003848:0.012604:0.005528:0.005330:0.010564:0.010660:0.010660:0.328704
◊:@0.541329:0.382592:0.546871:0.382592:0.546871:0.373407:0.541329:0.373407:0.005542
>1 focal lesions on MRI studies:@0.093867:0.404377:0.371151:0.404377:0.371151:0.388621:0.093867:0.388621:0.011661:0.010660:0.005330:0.006042:0.012604:0.012450:0.013143:0.003848:0.005330:0.003848:0.012508:0.007466:0.003848:0.012604:0.011738:0.007466:0.005330:0.012604:0.011738:0.005330:0.017684:0.011680:0.004349:0.005330:0.007466:0.006523:0.011699:0.013181:0.003848:0.012508:0.007466
§:@0.371144:0.398761:0.378044:0.398761:0.378044:0.389576:0.371144:0.389576:0.006899
Definition of smouldering multiple myeloma:@0.093868:0.428885:0.490252:0.428885:0.490252:0.412852:0.093868:0.412852:0.013277:0.012123:0.004907:0.004897:0.011353:0.004426:0.005580:0.004426:0.012123:0.011353:0.005195:0.012123:0.005195:0.005195:0.008274:0.017895:0.012123:0.011353:0.004426:0.012508:0.012123:0.005965:0.004426:0.011353:0.012508:0.005195:0.017895:0.011353:0.004426:0.005580:0.004426:0.012508:0.004426:0.012123:0.005195:0.017895:0.010968:0.012123:0.004426:0.012123:0.017895:0.012700
Both criteria must be met::@0.093868:0.453386:0.331319:0.453386:0.331319:0.437352:0.093868:0.437352:0.011161:0.012315:0.005773:0.011545:0.005388:0.012315:0.006158:0.004618:0.005773:0.012315:0.006158:0.004618:0.012700:0.005388:0.018088:0.011545:0.008467:0.005773:0.005388:0.012700:0.012315:0.005388:0.018088:0.012315:0.005773:0.005388
Serum monoclonal protein (IgG or IgA) ≥30 g/L or urinary monoclonal protein ≥500 mg :@0.093868:0.469552:0.898019:0.469552:0.898019:0.453796:0.093868:0.453796:0.009583:0.012508:0.005792:0.011699:0.018049:0.005330:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013123:0.005694:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.007100:0.004349:0.012950:0.016779:0.005330:0.012604:0.005792:0.005330:0.004349:0.012950:0.014239:0.007100:0.005330:0.010564:0.010660:0.010660:0.005330:0.012950:0.008409:0.008890:0.005330:0.012604:0.005792:0.005330:0.011699:0.005792:0.003848:0.011738:0.013143:0.005792:0.010314:0.005330:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013123:0.005651:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.010564:0.010660:0.010660:0.010660:0.005330:0.018049:0.012950:0.005330
per 24 hours and/or clonal bone-marrow plasma cells 10 to 60%:@0.093868:0.485718:0.684902:0.485718:0.684902:0.469962:0.093868:0.469962:0.013123:0.012508:0.005792:0.005330:0.010660:0.010660:0.005330:0.011738:0.012604:0.011699:0.005792:0.007466:0.005330:0.013143:0.011738:0.013181:0.008409:0.012604:0.005792:0.005330:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013123:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005680:0.012604:0.015990:0.005330:0.013123:0.003848:0.013143:0.007466:0.018049:0.013143:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.010660:0.010660:0.005330:0.006523:0.012604:0.005330:0.010660:0.010660:0.014913
Absence of myeloma-defining events or amyloidosis:@0.093868:0.501884:0.579604:0.501884:0.579604:0.486128:0.093868:0.486128:0.014239:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.006388:0.013181:0.012508:0.004686:0.004686:0.011738:0.003848:0.011738:0.012950:0.005330:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.012604:0.005792:0.005330:0.013143:0.018049:0.010314:0.003848:0.012604:0.003848:0.013181:0.012604:0.007466:0.003848:0.007466
Definition of monoclonal gammopathy of undetermined significance:@0.093868:0.526384:0.720958:0.526384:0.720958:0.510351:0.093868:0.510351:0.013277:0.012123:0.004907:0.004897:0.011353:0.004426:0.005580:0.004426:0.012123:0.011353:0.005195:0.012123:0.005195:0.005195:0.017895:0.012123:0.011353:0.012123:0.012123:0.004426:0.012123:0.011353:0.012508:0.004426:0.005195:0.012508:0.012508:0.017895:0.017895:0.012123:0.012508:0.012508:0.005580:0.011353:0.010968:0.005195:0.012123:0.005195:0.005195:0.011353:0.011353:0.012508:0.012123:0.005580:0.012123:0.005965:0.017895:0.004426:0.011353:0.012123:0.012508:0.005195:0.008274:0.004426:0.012508:0.011353:0.004426:0.004907:0.004897:0.012123:0.012508:0.011353:0.012123:0.012315
All three criteria must be met::@0.093868:0.550885:0.367495:0.550885:0.367495:0.534851:0.093868:0.534851:0.014239:0.004618:0.004618:0.005388:0.005773:0.011545:0.006158:0.012315:0.012315:0.005388:0.012315:0.006158:0.004618:0.005773:0.012315:0.006158:0.004618:0.012700:0.005388:0.018088:0.011545:0.008467:0.005773:0.005388:0.012700:0.012315:0.005388:0.018088:0.012315:0.005773:0.005388
Serum monoclonal protein <30 g/L:@0.093868:0.567051:0.414714:0.567051:0.414714:0.551295:0.093868:0.551295:0.009583:0.012508:0.005792:0.011699:0.018049:0.005330:0.018049:0.012604:0.011738:0.012604:0.012450:0.003848:0.012604:0.011738:0.013143:0.003848:0.005330:0.013123:0.005694:0.012604:0.006523:0.012508:0.003848:0.011738:0.005330:0.011661:0.010660:0.010660:0.005330:0.012950:0.008409:0.008890
Bone-marrow plasma cells <10%:@0.093868:0.583217:0.392213:0.583217:0.392213:0.567461:0.093868:0.567461:0.011045:0.012604:0.011738:0.012508:0.006388:0.018049:0.013143:0.005792:0.005707:0.012604:0.015990:0.005330:0.013123:0.003848:0.013143:0.007466:0.018049:0.013143:0.005330:0.012450:0.012508:0.003848:0.003848:0.007466:0.005330:0.011661:0.010660:0.010660:0.014913
Absence of myeloma-defining events or amyloidosis (or Waldenström :@0.093868:0.599383:0.743420:0.599383:0.743420:0.583627:0.093868:0.583627:0.014239:0.013123:0.007466:0.012508:0.011738:0.012450:0.012508:0.005330:0.012604:0.006042:0.005330:0.018049:0.010314:0.012508:0.003848:0.012604:0.018049:0.013143:0.006388:0.013181:0.012508:0.004686:0.004686:0.011738:0.003848:0.011738:0.012950:0.005330:0.012508:0.010660:0.012508:0.011738:0.006523:0.007466:0.005330:0.012604:0.005792:0.005330:0.013143:0.018049:0.010314:0.003848:0.012604:0.003848:0.013181:0.012604:0.007466:0.003848:0.007466:0.005330:0.007100:0.012604:0.005792:0.005330:0.017478:0.013143:0.003848:0.013181:0.012508:0.011738:0.007466:0.006523:0.005792:0.012604:0.018049:0.005330
macroglobulinemia in the case of IgM MGUS):@0.093868:0.615549:0.518315:0.615549:0.518315:0.599793:0.093868:0.599793:0.018049:0.013143:0.012450:0.005713:0.012604:0.012950:0.003848:0.012604:0.013123:0.011699:0.003848:0.003848:0.011738:0.012508:0.018049:0.003848:0.013143:0.005330:0.003848:0.011738:0.005330:0.006523:0.011738:0.012508:0.005330:0.012450:0.013143:0.007466:0.012508:0.005330:0.012604:0.006042:0.005330:0.004349:0.012950:0.017684:0.005330:0.017684:0.016779:0.012604:0.009583:0.007100
PET-CT: 18F-fluorodeoxyglucose positron emission tomography with computed tomography.:@0.084242:0.644323:0.841182:0.644323:0.841182:0.630317:0.084242:0.630317:0.010126:0.009168:0.007286:0.005679:0.013906:0.007328:0.004738:0.004738:0.009476:0.009476:0.008296:0.005679:0.004148:0.004148:0.010399:0.011203:0.005071:0.011203:0.011716:0.011118:0.011203:0.008210:0.009168:0.011511:0.003421:0.010399:0.011067:0.011203:0.006636:0.011118:0.004738:0.011665:0.011203:0.006636:0.003421:0.005798:0.005068:0.011203:0.010434:0.004738:0.011118:0.016044:0.003421:0.006636:0.006636:0.003421:0.011203:0.010434:0.004738:0.005798:0.011203:0.016044:0.011203:0.011511:0.005148:0.011682:0.011665:0.010434:0.009168:0.004738:0.014214:0.003421:0.005798:0.010434:0.004738:0.011067:0.011203:0.016044:0.011665:0.010399:0.005798:0.011118:0.011716:0.004738:0.005798:0.011203:0.016044:0.011203:0.011511:0.005148:0.011682:0.011665:0.010434:0.009168:0.004738
* Clonality should be established by showing kappa/lambda-light-chain restriction on flow :@0.084242:0.658434:0.831446:0.658434:0.831446:0.644428:0.084242:0.644428:0.007269:0.004738:0.013906:0.003421:0.011203:0.010434:0.011682:0.003421:0.003421:0.005798:0.009168:0.004738:0.006636:0.010434:0.011203:0.010399:0.003421:0.011716:0.004738:0.011665:0.011118:0.004738:0.011118:0.006636:0.005798:0.011682:0.011665:0.003421:0.003421:0.006636:0.010434:0.011118:0.011716:0.004738:0.011665:0.009168:0.004738:0.006636:0.010434:0.011203:0.014214:0.003421:0.010434:0.011511:0.004738:0.008586:0.011682:0.011665:0.011665:0.011682:0.007475:0.003421:0.011682:0.016044:0.011665:0.011716:0.011682:0.005679:0.003421:0.003421:0.011511:0.010434:0.005798:0.005679:0.011067:0.010434:0.011682:0.003421:0.010434:0.004738:0.005097:0.011118:0.006636:0.005798:0.005148:0.003421:0.011067:0.005798:0.003421:0.011203:0.010434:0.004738:0.011203:0.010434:0.004738:0.004148:0.004148:0.011203:0.014214:0.004738
cytometry, immunohistochemistry, or immunofluorescence. Bone-marrow plasma cell percentage :@0.084242:0.672545:0.898432:0.672545:0.898432:0.658540:0.084242:0.658540:0.011067:0.009168:0.005798:0.011203:0.016044:0.011118:0.005798:0.005148:0.009168:0.004738:0.004738:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.010434:0.003421:0.006636:0.005798:0.011203:0.011067:0.010434:0.011118:0.016044:0.003421:0.006636:0.005798:0.005148:0.009168:0.004738:0.004738:0.011203:0.005148:0.004738:0.003421:0.016044:0.016044:0.010399:0.010434:0.011203:0.004148:0.004148:0.010399:0.011203:0.005029:0.011118:0.006636:0.011067:0.011118:0.010434:0.011067:0.011118:0.004738:0.004738:0.009818:0.011203:0.010434:0.011118:0.005679:0.016044:0.011682:0.005148:0.005061:0.011203:0.014214:0.004738:0.011665:0.003421:0.011682:0.006636:0.016044:0.011682:0.004738:0.011067:0.011118:0.003421:0.003421:0.004738:0.011665:0.011118:0.005036:0.011067:0.011118:0.010434:0.005798:0.011682:0.011511:0.011118:0.004738
should preferably be estimated from a core biopsy specimen; in case of a disparity between the :@0.084242:0.686656:0.887321:0.686656:0.887321:0.672651:0.084242:0.672651:0.006636:0.010434:0.011203:0.010399:0.003421:0.011716:0.004738:0.011665:0.005078:0.011118:0.005371:0.011118:0.005148:0.011682:0.011665:0.003421:0.009168:0.004738:0.011665:0.011118:0.004738:0.011118:0.006636:0.005798:0.003421:0.016044:0.011682:0.005798:0.011118:0.011716:0.004738:0.005371:0.005073:0.011203:0.016044:0.004738:0.011682:0.004738:0.011067:0.011203:0.005066:0.011118:0.004738:0.011665:0.003421:0.011203:0.011665:0.006636:0.009168:0.004738:0.006636:0.011665:0.011118:0.011067:0.003421:0.016044:0.011118:0.010434:0.004738:0.004738:0.003421:0.010434:0.004738:0.011067:0.011682:0.006636:0.011118:0.004738:0.011203:0.005371:0.004738:0.011682:0.004738:0.011716:0.003421:0.006636:0.011665:0.011682:0.005148:0.003421:0.005798:0.009168:0.004738:0.011665:0.011118:0.005798:0.014214:0.011118:0.011118:0.010434:0.004738:0.005798:0.010434:0.011118:0.004738
aspirate and core biopsy, the highest value should be used.:@0.084242:0.700767:0.578825:0.700767:0.578825:0.686762:0.084242:0.686762:0.011682:0.006636:0.011665:0.003421:0.005148:0.011682:0.005798:0.011118:0.004738:0.011682:0.010434:0.011716:0.004738:0.011067:0.011203:0.005073:0.011118:0.004738:0.011665:0.003421:0.011203:0.011665:0.006636:0.009168:0.004738:0.004738:0.005798:0.010434:0.011118:0.004738:0.010434:0.003421:0.011511:0.010434:0.011118:0.006636:0.005798:0.004738:0.009476:0.011682:0.003421:0.010399:0.011118:0.004738:0.006636:0.010434:0.011203:0.010399:0.003421:0.011716:0.004738:0.011665:0.011118:0.004738:0.010399:0.006636:0.011118:0.011716:0.004738
¶:@0.084242:0.716524:0.092743:0.716524:0.092743:0.700661:0.084242:0.700661:0.008501
 Measured or estimated by validated equations.:@0.092743:0.714878:0.492281:0.714878:0.492281:0.700873:0.092743:0.700873:0.004738:0.015719:0.011118:0.011682:0.006636:0.010399:0.005077:0.011118:0.011716:0.004738:0.011203:0.005148:0.004738:0.011118:0.006636:0.005798:0.003421:0.016044:0.011682:0.005798:0.011118:0.011716:0.004738:0.011665:0.009168:0.004738:0.009476:0.011682:0.003421:0.003421:0.011716:0.011682:0.005798:0.011118:0.011716:0.004738:0.011118:0.011665:0.010399:0.011682:0.005798:0.003421:0.011203:0.010434:0.006636:0.004738
Δ:@0.084242:0.730636:0.095206:0.730636:0.095206:0.714772:0.084242:0.714772:0.010964
 If bone marrow has less than 10% clonal plasma cells, more than one bone lesion is required to :@0.095206:0.728989:0.883948:0.728989:0.883948:0.714984:0.095206:0.714984:0.004738:0.003866:0.005371:0.004738:0.011665:0.011203:0.010434:0.011118:0.004738:0.016044:0.011682:0.005148:0.005063:0.011203:0.014214:0.004738:0.010434:0.011682:0.006636:0.004738:0.003421:0.011118:0.006636:0.006636:0.004738:0.005798:0.010434:0.011682:0.010434:0.004738:0.009476:0.009476:0.013256:0.004738:0.011067:0.003421:0.011203:0.010434:0.011682:0.003421:0.004738:0.011665:0.003421:0.011682:0.006636:0.016044:0.011682:0.004738:0.011067:0.011118:0.003421:0.003421:0.006636:0.004738:0.004738:0.016044:0.011203:0.005082:0.011118:0.004738:0.005798:0.010434:0.011682:0.010434:0.004738:0.011203:0.010434:0.011118:0.004738:0.011665:0.011203:0.010434:0.011118:0.004738:0.003421:0.011118:0.006636:0.003421:0.011203:0.010434:0.004738:0.003421:0.006636:0.004738:0.005051:0.011118:0.011665:0.010399:0.003421:0.005082:0.011118:0.011716:0.004738:0.005798:0.011203:0.004738
distinguish from solitary plasmacytoma with minimal marrow involvement.:@0.084242:0.743100:0.689894:0.743100:0.689894:0.729095:0.084242:0.729095:0.011716:0.003421:0.006636:0.005798:0.003421:0.010434:0.011511:0.010399:0.003421:0.006636:0.010434:0.004738:0.005371:0.005082:0.011203:0.016044:0.004738:0.006636:0.011203:0.003421:0.003421:0.005798:0.011682:0.005148:0.009168:0.004738:0.011665:0.003421:0.011682:0.006636:0.016044:0.011682:0.011067:0.009168:0.005798:0.011203:0.016044:0.011682:0.004738:0.014214:0.003421:0.005798:0.010434:0.004738:0.016044:0.003421:0.010434:0.003421:0.016044:0.011682:0.003421:0.004738:0.016044:0.011682:0.005148:0.005082:0.011203:0.014214:0.004738:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.011118:0.016044:0.011118:0.010434:0.005798:0.004738
◊:@0.084242:0.758858:0.093752:0.758858:0.093752:0.742994:0.084242:0.742994:0.009510
 These values are based on the serum Freelite assay (The Binding Site Group, Birmingham, UK). The :@0.093752:0.757211:0.904916:0.757211:0.904916:0.743206:0.093752:0.743206:0.004738:0.007286:0.010434:0.011118:0.006636:0.011118:0.004738:0.009476:0.011682:0.003421:0.010399:0.011118:0.006636:0.004738:0.011682:0.005075:0.011118:0.004738:0.011665:0.011682:0.006636:0.011118:0.011716:0.004738:0.011203:0.010434:0.004738:0.005798:0.010434:0.011118:0.004738:0.006636:0.011118:0.005148:0.010399:0.016044:0.004738:0.008296:0.005051:0.011118:0.011118:0.003421:0.003421:0.005798:0.011118:0.004738:0.011682:0.006636:0.006636:0.011682:0.009168:0.004738:0.006312:0.007286:0.010434:0.011118:0.004738:0.009818:0.003421:0.010434:0.011716:0.003421:0.010434:0.011511:0.004738:0.008518:0.003421:0.005798:0.011118:0.004738:0.014915:0.005078:0.011203:0.010399:0.011665:0.004738:0.004738:0.009818:0.003421:0.005619:0.016044:0.003421:0.010434:0.011511:0.010434:0.011682:0.016044:0.004738:0.004738:0.011203:0.010109:0.006312:0.004738:0.004738:0.007286:0.010434:0.011118:0.004738
involved free light chain must be ≥100 mg/L.:@0.084242:0.771323:0.449131:0.771323:0.449131:0.757317:0.084242:0.757317:0.003421:0.010434:0.009476:0.011203:0.003421:0.009476:0.011118:0.011716:0.004738:0.005371:0.005082:0.011118:0.011118:0.004738:0.003421:0.003421:0.011511:0.010434:0.005798:0.004738:0.011067:0.010434:0.011682:0.003421:0.010434:0.004738:0.016044:0.010399:0.006636:0.005798:0.004738:0.011665:0.011118:0.004738:0.009390:0.009476:0.009476:0.009476:0.004738:0.016044:0.011511:0.007475:0.007902:0.004738
§:@0.084242:0.788397:0.092401:0.788397:0.092401:0.772534:0.084242:0.772534:0.008159
 Each focal lesion must be 5 mm or more in size.:@0.092401:0.786751:0.485875:0.786751:0.485875:0.772745:0.092401:0.772745:0.004738:0.009168:0.011682:0.011067:0.010434:0.004738:0.005371:0.011203:0.011067:0.011682:0.003421:0.004738:0.003421:0.011118:0.006636:0.003421:0.011203:0.010434:0.004738:0.016044:0.010399:0.006636:0.005798:0.004738:0.011665:0.011118:0.004738:0.009476:0.004738:0.016044:0.016044:0.004738:0.011203:0.005148:0.004738:0.016044:0.011203:0.005051:0.011118:0.004738:0.003421:0.010434:0.004738:0.006636:0.003421:0.007269:0.011118:0.004738
Source: Adapted from Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma  :@0.084242:0.807996:0.773516:0.807996:0.773516:0.795741:0.084242:0.795741:0.007453:0.009803:0.009100:0.004505:0.009683:0.009728:0.004146:0.004146:0.011075:0.010252:0.010222:0.010207:0.005074:0.009728:0.010252:0.004146:0.004699:0.004505:0.009803:0.014038:0.004146:0.009085:0.010222:0.003038:0.007513:0.009100:0.014038:0.010222:0.004505:0.004146:0.007453:0.010506:0.004146:0.004146:0.011135:0.002993:0.014038:0.009803:0.010207:0.009803:0.009100:0.002993:0.009803:0.005807:0.004146:0.013754:0.011075:0.004146:0.004146:0.008860:0.010222:0.002993:0.009100:0.014038:0.010207:0.009803:0.004146:0.011075:0.004146:0.004146:0.009728:0.005074:0.004146:0.010222:0.002993:0.004146:0.004146:0.003382:0.009129:0.005074:0.009728:0.004505:0.009129:0.010222:0.005074:0.002993:0.009803:0.009129:0.010222:0.002993:0.004146:0.013754:0.008022:0.009728:0.002993:0.009803:0.014038:0.010222:0.004071:0.004146
Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15 (12):e538-e548.:@0.084242:0.821228:0.875856:0.821228:0.875856:0.808973:0.084242:0.808973:0.014368:0.009803:0.004505:0.007513:0.002993:0.009129:0.010072:0.004146:0.013051:0.004505:0.009803:0.009100:0.010207:0.004146:0.009100:0.010207:0.010252:0.010222:0.005074:0.009728:0.010252:0.004146:0.009683:0.004505:0.002993:0.005074:0.009728:0.004505:0.002993:0.010222:0.004146:0.004699:0.009803:0.004505:0.004146:0.005074:0.009129:0.009728:0.004146:0.010252:0.002993:0.010222:0.010072:0.009129:0.009803:0.005807:0.002993:0.005807:0.004146:0.009803:0.004699:0.004146:0.014038:0.009100:0.002993:0.005074:0.002993:0.010207:0.002993:0.009728:0.004146:0.014038:0.008022:0.009728:0.002993:0.009803:0.014038:0.010222:0.004146:0.004146:0.006914:0.010222:0.009129:0.009683:0.009728:0.005074:0.004146:0.013006:0.009129:0.009683:0.009803:0.002993:0.004146:0.004146:0.008291:0.008291:0.008291:0.008291:0.004146:0.008291:0.008291:0.004146:0.005523:0.008291:0.008291:0.005523:0.004146:0.009728:0.008291:0.008291:0.008291:0.004969:0.009728:0.008291:0.008291:0.008291:0.004146